NRx Pharmaceuticals, Inc. (NRXP)Healthcare | Biotechnology | Wilmington, United States | NasdaqCM
2.55 USD
+0.04
(1.594%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 2.55 Short-term: ★★★★☆ | Long-term: ★★☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 18, 2026, 6:02 p.m. EDT
NRXP is a textbook high-volatility biotech play masquerading as a fundamental turnaround: while the balance sheet remains precarious with negative book value and burn rates, the market has completely ignored the math in favor of binary FDA catalysts. The 4 analysts unanimously rating it 'Strong Buy' with a mean target of $38 (a 15x jump from current levels) are pricing in a total de-risking of the pipeline that the forecast model (Ljung-Box p-value near zero) suggests is statistically noise-ridden for short-term prediction. The options market is screaming 'moonshot,' with speculators overwhelmingly betting on a 100%+ rally, but the lack of dividends and negative cash flow makes this a dangerous 'hope-trading' instrument for long-term capital preservation. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.105239 |
| AutoETS | 0.113387 |
| MSTL | 0.114816 |
| AutoARIMA | 0.114997 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 80% |
| H-stat | 0.57 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.205 |
| Excess Kurtosis | -1.16 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Revenue per Share | 0.057 |
| Market Cap | 84,322,456 |
| Forward P/E | 19.62 |
| Beta | 1.83 |
| Previous Name | NeuroRx, Inc. |
| Website | https://www.nrxpharma.com |
As of April 18, 2026, 6:02 p.m. EDT: Speculators are displaying a distinct bullish skew in the options market, particularly in the mid-term June 2026 expiration where 78% of Open Interest is concentrated in OTM calls (5.0 and 7.5 strikes) compared to negligible put volume. The September data shows a balanced split between ITM and OTM calls, indicating sustained long-term upside expectations, while the May expiration shows heavy ATM positioning (305 OTM puts vs 152 ITM calls) likely serving as a short-term hedge or straddle around the current price. Despite high implied volatility (IV ~108-151%), the volume is heavily skewed to calls, signaling that the market is pricing in a potential breakout event rather than a downturn.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.36363637 |
| Address1 | 1,201 Orange Street |
| Address2 | Suite 600 |
| All Time High | 769.9 |
| All Time Low | 1.1 |
| Ask | 3.21 |
| Ask Size | 2 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 834,960 |
| Average Daily Volume3 Month | 710,340 |
| Average Volume | 710,340 |
| Average Volume10Days | 834,960 |
| Beta | 1.83 |
| Bid | 1.85 |
| Bid Size | 2 |
| Book Value | -0.503 |
| City | Wilmington |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 2.55 |
| Current Ratio | 0.311 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 2.575 |
| Day Low | 2.49 |
| Display Name | NRx Pharmaceuticals |
| Earnings Call Timestamp End | 1,774,353,600 |
| Earnings Call Timestamp Start | 1,774,353,600 |
| Earnings Timestamp | 1,774,355,400 |
| Earnings Timestamp End | 1,778,848,200 |
| Earnings Timestamp Start | 1,778,848,200 |
| Ebitda | -16,118,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -4.782 |
| Enterprise To Revenue | 62.916 |
| Enterprise Value | 77,072,576 |
| Eps Current Year | 0.13 |
| Eps Forward | 0.13 |
| Eps Trailing Twelve Months | -1.34 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 2.0009 |
| Fifty Day Average Change | 0.5490999 |
| Fifty Day Average Change Percent | 0.27442646 |
| Fifty Two Week Change Percent | 36.363636 |
| Fifty Two Week High | 3.84 |
| Fifty Two Week High Change | -1.29 |
| Fifty Two Week High Change Percent | -0.3359375 |
| Fifty Two Week Low | 1.62 |
| Fifty Two Week Low Change | 0.92999995 |
| Fifty Two Week Low Change Percent | 0.57407403 |
| Fifty Two Week Range | 1.62 - 3.84 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,512,397,800,000 |
| Float Shares | 24,244,853 |
| Forward Eps | 0.13 |
| Forward P E | 19.615385 |
| Free Cashflow | -805,875 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 29 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.58776003 |
| Gross Profits | 720,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.08304 |
| Held Percent Institutions | 0.25163 |
| Implied Shares Outstanding | 33,067,630 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,712,016,000 |
| Last Split Factor | 1:10 |
| Long Business Summary | NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder, and chronic pain. Its lead drug candidates include NRX-101, an oral, fixed dosed combination of D-cycloserine and lurasidone for suicidal treatment-resistant bipolar depression in patients with sub-acute suicidal ideation and behavior in phase 2 trial; and NRX-100, a preservative-free formulation of ketamine for intravenous infusion and for the treatment of suicidal depression. The company has a license agreement with Alvogen, Inc. and Lotus Pharmaceutical Co. Ltd.; Apkarian Technologies; development and license agreement with Glytech, LLC; and Sarah Herzog Memorial Hospital; and has as a partnership with neurocare Group AG to create a nationwide network of clinics to offer integrated neuroplastic care for the treatment of Depression, PTSD, and other serious mental health disorders. NRx Pharmaceuticals, Inc. was founded in 2015 and is based in Wilmington, Delaware. |
| Long Name | NRx Pharmaceuticals, Inc. |
| Market | us_market |
| Market Cap | 84,322,456 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_319388181 |
| Most Recent Quarter | 1,767,139,200 |
| Name Change Date | 2,026-04-19 |
| Net Income To Common | -28,622,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 84,322,456 |
| Number Of Analyst Opinions | 4 |
| Open | 2.54 |
| Operating Cashflow | -14,112,000 |
| Operating Margins | -4.67345 |
| Payout Ratio | 0.0 |
| Phone | 484 254 6134 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 2.55 |
| Post Market Time | 1,776,470,291 |
| Prev Name | NeuroRx, Inc. |
| Previous Close | 2.51 |
| Price Eps Current Year | 19.615385 |
| Price Hint | 4 |
| Price To Book | -5.069582 |
| Price To Sales Trailing12 Months | 68.834656 |
| Profit Margins | 0.0 |
| Quick Ratio | 0.278 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | 0.04 |
| Regular Market Change Percent | 1.59362 |
| Regular Market Day High | 2.575 |
| Regular Market Day Low | 2.49 |
| Regular Market Day Range | 2.49 - 2.575 |
| Regular Market Open | 2.54 |
| Regular Market Previous Close | 2.51 |
| Regular Market Price | 2.55 |
| Regular Market Time | 1,776,456,000 |
| Regular Market Volume | 1,078,039 |
| Return On Assets | -1.21846 |
| Revenue Per Share | 0.057 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 33,067,630 |
| Shares Percent Shares Out | 0.0759 |
| Shares Short | 2,511,228 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 2,459,826 |
| Short Name | NRX Pharmaceuticals, Inc. |
| Short Percent Of Float | 0.0802 |
| Short Ratio | 3.01 |
| Source Interval | 15 |
| State | DE |
| Symbol | NRXP |
| Target High Price | 48.0 |
| Target Low Price | 25.0 |
| Target Mean Price | 38.0 |
| Target Median Price | 39.5 |
| Total Cash | 7,797,000 |
| Total Cash Per Share | 0.236 |
| Total Debt | 631,000 |
| Total Revenue | 1,225,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.34 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 2.514475 |
| Two Hundred Day Average Change | 0.035524845 |
| Two Hundred Day Average Change Percent | 0.0141281355 |
| Type Disp | Equity |
| Volume | 1,078,039 |
| Website | https://www.nrxpharma.com |
| Zip | 19,801 |